Shattuck Labs, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Shattuck Labs, Inc. (STTK) reported Debt Securities, Available-for-sale, Unrealized Loss of $497.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2022-03-15
- Shattuck Labs, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2021 was $497.00K, a 324.79% increase from fiscal 2020.
- Shattuck Labs, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2020 was $117.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|
| 2021-12-31 | $497.00K 10-K · filed 2022-03-15 |
| 2020-12-31 | $117.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |